Healthcare Industry News: Ipsen
News Release - April 16, 2007
Ipsen Appoints Sean McKercher as Vice President of Commercial Development in North AmericaPARIS--(HSMN NewsFeed)--Regulatory News: Ipsen (Euronext: FR0010259150)(Paris:IPN ) today announced the appointment of Sean McKercher to the company's newly established position of Vice President of Commercial Development in North America, effective immediately. Ipsen created this new position as a result of the strong development of its commercial activities and partnerships in this region and in order to better seize the large business opportunities that arise in North America.
In his new role, Sean McKercher will report to Christophe Jean, Ipsen's Executive Vice President and Chief Operating Officer, and will be based in the company's Boston office. Sean McKercher will be responsible to oversee the management of the company's various U.S. drug partnerships and participate in the development of Ipsen's North American business strategy and its implementation.
Sean has 25 years of experience in the pharmaceutical industry, most recently with Abbott Laboratories. While at Abbott Lab's he served in many leadership roles including Business Unit Manager Specialty Pharmaceuticals Abbott Canada, Commercial Director Pacific/Asia/Africa Region, General Manager South Africa and Region Africa prior to his most recent set of roles in Abbott's US pharmaceutical division. While in the US he was General Manager of the Strategic Alliance Franchise, Abbott's $2 billion in sales co-promotion agreement with Boehringer Ingelheim, General Manager for Abbott's leading antibiotic Biaxin and most recently General Manager of Marketing and Sales Operations where he led a team of 200 people in providing support to all of Abbott's U.S. pharmaceutical commercial teams.
Ipsen is an innovation driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2006, R&D expenditure was EUR 178.3 million, i.e. 20.7% of consolidated sales, which amounted to EUR 861.7 million while total revenues amounted to EUR 945.3 million (in IFRS). 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen's shares are traded on Segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN code: FR0010259150). Ipsen' s shares are eligible to the "Systeme a Reglement Differe" ("SRD") and the Group is part of the SBF 250 index. For more information on Ipsen, visit our website at www.Ipsen.com.
The forward-looking statements and targets contained herein are based on Ipsen's management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein.
Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its information documents filed with the French Autorite des marches financiers.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.